Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery

Fig. 3

Median RFS was significantly poorer for lung cancer patients with the Exon 21 L858R point mutation (n = 45) than those with the Exon 19 deletion (n = 56); median RFS were 14.7 months and 28.4 months, respectively (p = 0.001). No significant differences were observed between the two EGFR mutations; median PRS were 29.5 months and 38.0 months, respectively (p = 0.525)

Back to article page